Covalent Polymer‐RNA Conjugates for Potent Activation of the RIG‐I Pathway
Authors:
- Christian R. PalmerCPChristian R. Palmer
- Blaise R. KimmelBKBlaise R. Kimmel
- Hayden M. PagendarmHPHayden M. Pagendarm
- Alexander J. KwiatkowskiAKAlexander J. Kwiatkowski
- Payton T. StonePSPayton T. Stone
- Karan AroraKAKaran Arora
- Nora FranciniNFNora Francini
- Anna M. PyleAPAnna M. Pyle
- John T. WilsonJWJohn T. Wilson
Open Access
- 3 May 2024
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (5) , e2303815
Abstract
RNA ligands of retinoic acid‐inducible gene I (RIG‐I) are a promising class of oligonucleotide therapeutics with broad potential as antiviral agents, vaccine adjuvants, and cancer immunotherapies. However, their translation has been limited by major drug delivery barriers, including poor cellular uptake, nuclease degradation, and an inability to access the cytosol where RIG‐I is localized. Here this challenge is addressed by engineering nanoparticles that harness covalent conjugation of 5′‐triphospate RNA (3pRNA) to endosome‐destabilizing polymers. Compared to 3pRNA loaded into analogous nanoparticles via electrostatic interactions, it is found that covalent conjugation of 3pRNA improves loading efficiency, enhances immunostimulatory activity, protects against nuclease degradation, and improves serum stability. Additionally, it is found that 3pRNA could be conjugated via either a disulfide or thioether linkage, but that the latter is only permissible if conjugated distal to the 5′‐triphosphate group. Finally, administration of 3pRNA‐polymer conjugates to mice significantly increases type‐I interferon levels relative to analogous carriers that use electrostatic 3pRNA loading. Collectively, these studies have yielded a next‐generation polymeric carrier for in vivo delivery of 3pRNA, while also elucidating new chemical design principles for covalent conjugation of 3pRNA with potential to inform the further development of therapeutics and delivery technologies for pharmacological activation of RIG‐I.Keywords
Funding Information
- National Institute of General Medical Sciences (T32GM065086)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK101003)
- Vanderbilt Cancer Center (Ambassador Discovery Grant)
- Pharmaceutical Research and Manufacturers of America Foundation (Postdoctoral Fellowship In Drug Delivery)
- Congressionally Directed Medical Research Programs (W81XWH‐20‐1‐0624)
- National Institute of Biomedical Imaging and Bioengineering (R01EB033822)
- National Science Foundation (CBET‐1554623)
- National Cancer Institute (T32CA009592)
This publication has 72 references indexed in Scilit:
- Determination of Optimum Ratio of Cationic Polymers and Small Interfering RNA with Agarose Gel Retardation Assay2022
- Kupffer cell release of platelet activating factor drives dose limiting toxicities of nucleic acid nanocarriersBiomaterials, 2021
- Strategies in the design of endosomolytic agents for facilitating endosomal escape in nanoparticlesBiochimie, 2019
- RIG-I Selectively Discriminates against 5′-Monophosphate RNACell Reports, 2019
- Investigation of charge ratio variation in mRNA – DEAE-dextran polyplex delivery systemsBiomaterials, 2019
- Type I interferons in viral control and immune regulationCurrent Opinion in Virology, 2016
- Acidic pH‐Responsive siRNA Conjugate for Reversible Carrier Stability and Accelerated Endosomal Escape with Reduced IFNα‐Associated Immune ResponseAngewandte Chemie International Edition, 2013
- Solid‐Phase Chemical Synthesis of 5′‐Triphosphate DNA, RNA, and Chemically Modified OligonucleotidesCurrent Protocols in Nucleic Acid Chemistry, 2012
- Interferon-stimulated genes and their antiviral effector functionsCurrent Opinion in Virology, 2011
- The role of glutathione in cancerCell Biochemistry and Function, 2004